BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bernaitis N, Ching CK, Chen L, Hon JS, Teo SC, Davey AK, Anoopkumar-Dukie S. The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score Predicts Warfarin Control in a Singaporean Population.J Stroke Cerebrovasc Dis. 2017;26:64-69. [PMID: 27671097 DOI: 10.1016/j.jstrokecerebrovasdis.2016.08.030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Lobos-bejarano JM, Castellanos Rodríguez A, Barrios V, Escobar C, Polo-garcía J, del Castillo-rodríguez JC, Vargas-ortega D, Lopez-pineda A, Prieto-valiente L, Lip GY; PAULA Study Team. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. Int J Clin Pract 2017;71:e12974. [DOI: 10.1111/ijcp.12974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Zawawi NA, Abdul Halim Zaki I, Ming LC, Goh HP, Zulkifly HH. Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation. Front Cardiovasc Med 2021;8:736143. [PMID: 34869639 DOI: 10.3389/fcvm.2021.736143] [Reference Citation Analysis]
3 Li Y, Yu J, Kuang Y, Wu C, Yang L, Fang Q, Pei Q, Yang G. Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study. Curr Med Res Opin 2020;36:1433-9. [PMID: 32677855 DOI: 10.1080/03007995.2020.1796611] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Chaterji S, Lian LG, Lee TY, Chua L, Wee SY, Yap SL, K DL, Tan NC. Factors influencing primary care physicians' prescribing behavior of anticoagulant therapy for the management of patients with non-valvular atrial fibrillation in Singapore: a qualitative research study. BMC Fam Pract 2021;22:101. [PMID: 34034648 DOI: 10.1186/s12875-021-01453-5] [Reference Citation Analysis]
5 Chia PL. Stroke prevention in atrial fibrillation: the Singapore story. Singapore Med J 2020;61:617-8. [PMID: 33415340 DOI: 10.11622/smedj.2020175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ding Z, Zhang C, Qian YY, Wang N, Gu ZC, Xu H, Zheng YL. Rationale and design of a prospective, multicenter, cross-sectional study of appropriateness evaluation of the prescription of non-vitamin K antagonist oral anticoagulants for Chinese atrial fibrillation patients (Chi-NOACs-AF trial). Ann Transl Med 2021;9:580. [PMID: 33987278 DOI: 10.21037/atm-20-6893] [Reference Citation Analysis]
7 Krittayaphong R, Winijkul A, Pirapatdit A, Chiewvit P, Komoltri C, Boonyapisit W, Arunsiriwattana S, Bunyapipat T, Apiyasawat S, Rattanasumawong K, Yindeengam A; Cool-AF Investigators. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. Singapore Med J 2020;61:641-6. [PMID: 31680175 DOI: 10.11622/smedj.2019143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Li YG, Lee SR, Choi EK, Lip GY. Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients. Korean Circ J. 2018;48:665-684. [PMID: 30073805 DOI: 10.4070/kcj.2018.0190] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
9 Rusdiana T, Mardhiani YD, Putriana NA, Gozali D, Nagano D, Araki T, Yamamoto K. The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies. Pharm Biol 2021;59:639-46. [PMID: 34062109 DOI: 10.1080/13880209.2021.1928716] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Alhmoud EN, Elewa H, Abdul Gelil MS, Abd El Samad OB, Elzouki AY. Evaluation of the Validity of SAMe-TT2R2 Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin. Clin Appl Thromb Hemost 2020;26:1076029620945039. [PMID: 32875827 DOI: 10.1177/1076029620945039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lip GY, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future: Comparing the guidelines and practical decision-making. Thromb Haemost 2017;117:1230-9. [DOI: 10.1160/th16-11-0876] [Cited by in Crossref: 244] [Cited by in F6Publishing: 61] [Article Influence: 48.8] [Reference Citation Analysis]
12 Phrommintikul A, Nathisuwan S, Gunaparn S, Krittayaphong R, Wongcharoen W, Sehmi S, Mehta S, Winkles N, Brocklehurst P, Mathers J, Jowett S, Jolly K, Lane D, Thomas GN, Lip GYH; TREATS-AF Study Group. Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TT2R2 score-guided strategy in anticoagulant-naïve Thai patients with atrial fibrillation (TREATS-AF): a study protocol. BMJ Open 2021;11:e051987. [PMID: 34635526 DOI: 10.1136/bmjopen-2021-051987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lip GY, Al-saady N, Jin J, Sun M, Melino M, Winters SM, Zamoryakhin D, Goette A. Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin – Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial). The American Journal of Cardiology 2017;120:792-6. [DOI: 10.1016/j.amjcard.2017.06.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
14 Sargin M, Erdogan SB, Bastopcu M, Arslanhan G, Tasdemir MM, Orhan G. Cost of Healthcare Associated With Deep Vein Thrombosis in Patients Treated With Warfarin in Turkey: 2010-2013 Database Analysis of a Tertiary Care Center. Value Health Reg Issues 2019;19:81-6. [PMID: 31254969 DOI: 10.1016/j.vhri.2019.03.007] [Reference Citation Analysis]
15 Chiang CE, Okumura K, Zhang S, Chao TF, Siu CW, Wei Lim T, Saxena A, Takahashi Y, Siong Teo W. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm 2017;33:345-67. [PMID: 28765771 DOI: 10.1016/j.joa.2017.05.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 16.0] [Reference Citation Analysis]
16 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
17 van Miert JHA, Bos S, Veeger NJGM, Meijer K. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PLoS One 2018;13:e0194208. [PMID: 29534092 DOI: 10.1371/journal.pone.0194208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Lip GY, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L. Antithrombotic Therapy for Atrial Fibrillation. Chest 2018;154:1121-201. [DOI: 10.1016/j.chest.2018.07.040] [Cited by in Crossref: 397] [Cited by in F6Publishing: 344] [Article Influence: 99.3] [Reference Citation Analysis]
19 Bernaitis N, Ching CK, Teo SC, Chen L, Badrick T, Davey AK, Crilly J, Anoopkumar-Dukie S. Factors influencing warfarin control in Australia and Singapore. Thromb Res 2017;157:120-5. [PMID: 28738273 DOI: 10.1016/j.thromres.2017.07.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
20 Zulkifly H, Lip GYH, Lane DA. Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. Heart Rhythm 2018;15:615-23. [PMID: 29180122 DOI: 10.1016/j.hrthm.2017.11.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]